leadf
logo-loader
viewMydecine Innovations Group Inc
(
OTC:MYCOFFRA:0NFANEO:MYCO
)

Mydecine Innovations Group: 'potential for big catalysts for share price as trials move forward'

Proactive Research analyst Ed Stacey presents his research on Mydecine Innovations Group ((NEO: MYCO) (OTCMKTS: MYCOF) a biotech company developing new treatments for mental health conditions, from natural sources, including psychedelic compounds.

Stacey explains Mydecine's unique differentiators, their telemedecine platform and their two drug programs which target PTSD and nicotine addiction. But worth noting IP protection.

He says the firm will leverage the expertise of a medical and scientific team that includes world-renowned practitioners in psychiatry and psychopharmacology.

The company also benefits from a strong network of external relationships with academic research partners and with companies specialised in delivering on pharmaceutical developments.

Click here to read Proactive analyst Ed Stacey's extensive research note on 'Mydecine Innovations Group: Initiation report'

 

Quick facts: Mydecine Innovations Group Inc

Follow
OTC:MYCOF

Price: 0.2773 USD

Market Cap: $66.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking...

Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) (NEO:MYCO) CEO Joshua Bartch tells Proactive it has partnered with Principal Investigator Dr Matthew Johnson of Johns Hopkins University on a study evaluating the administration of its lead drug candidate...

2 weeks, 3 days ago

2 min read